American National Insurance Co. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.2% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 77,310 shares of the company’s stock after selling 125 shares during the period. American National Insurance Co.’s holdings in Zoetis were worth $14,407,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of ZTS. Polen Capital Management LLC boosted its holdings in shares of Zoetis by 2.2% in the 1st quarter. Polen Capital Management LLC now owns 11,587,601 shares of the company’s stock valued at $1,824,815,000 after purchasing an additional 244,701 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Zoetis by 10.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,062,310 shares of the company’s stock valued at $1,584,612,000 after acquiring an additional 912,551 shares during the last quarter. Geode Capital Management LLC raised its stake in Zoetis by 0.7% during the first quarter. Geode Capital Management LLC now owns 7,585,607 shares of the company’s stock worth $1,191,202,000 after acquiring an additional 55,793 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Zoetis by 4.1% in the first quarter. Northern Trust Corp now owns 5,817,979 shares of the company’s stock worth $916,216,000 after acquiring an additional 228,477 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its stake in shares of Zoetis by 14.6% in the 1st quarter. UBS Asset Management Americas Inc. now owns 4,214,940 shares of the company’s stock valued at $663,769,000 after purchasing an additional 536,405 shares in the last quarter. Institutional investors own 89.53% of the company’s stock.
In other Zoetis news, CEO Kristin C. Peck sold 14,500 shares of the company’s stock in a transaction dated Wednesday, August 25th. The shares were sold at an average price of $203.55, for a total value of $2,951,475.00. Following the completion of the sale, the chief executive officer now directly owns 43,424 shares of the company’s stock, valued at approximately $8,838,955.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Willie M. Reed sold 1,450 shares of the company’s stock in a transaction that occurred on Monday, August 23rd. The shares were sold at an average price of $207.10, for a total value of $300,295.00. Following the completion of the transaction, the director now directly owns 5,964 shares of the company’s stock, valued at $1,235,144.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,003 shares of company stock worth $9,711,854. Company insiders own 0.17% of the company’s stock.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 5th. The company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.08 by $0.11. Zoetis had a return on equity of 53.87% and a net margin of 25.76%. During the same period in the prior year, the firm earned $0.89 earnings per share. Equities research analysts anticipate that Zoetis Inc. will post 4.53 earnings per share for the current fiscal year.
A number of analysts have weighed in on ZTS shares. Credit Suisse Group raised their target price on shares of Zoetis from $206.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, August 9th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $186.00 price objective on the stock in a research report on Tuesday, June 1st. Raymond James downgraded Zoetis from an “outperform” rating to a “market perform” rating in a research report on Friday, July 16th. Cantor Fitzgerald upped their price objective on Zoetis from $210.00 to $238.00 and gave the company an “overweight” rating in a research note on Tuesday, July 13th. Finally, Barclays lifted their target price on shares of Zoetis from $208.00 to $235.00 and gave the stock an “overweight” rating in a research report on Friday, August 6th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $199.08.
Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.
Featured Story: Federal Reserve
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.